Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 92-95, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vihko, P.
Right arrow Articles by Vihko, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vihko, P.
Right arrow Articles by Vihko, R.

Clinical Chemistry, Vol 36, 92-95, Copyright © 1990 by American Association for Clinical Chemistry

Time-resolved immunofluorometric assay of human prostate-specific antigen

P Vihko, R Kurkela, J Ramberg, I Pelkonen and R Vihko
Department of Clinical Chemistry, University of Oulu, Finland.

Assay of human serum prostate-specific antigen (PSA) is gaining importance in diagnosis and follow-up of prostatic cancer. In this time- resolved immunofluorometric assay of PSA, strip-wells were coated with a polyclonal antibody against PSA. To prepare the label, a monoclonal antibody displaying high affinity towards PSA was purified and derivatized with diethylenetriaminepentaacetic acid. With use of this derivative, seven to eight Eu atoms could be combined with one antibody molecule with no decrease in immunoreactivity. The minimum detectable concentration of PSA was 0.12 microgram/L. In 60 of 63 women studied, the PSA concentration in serum was less than 0.2 microgram/L. The increase in PSA in serum of asymptomatic men 51 years old or older, as compared with that for younger subjects, was possibly a result of "occult" prostatic hyperplasia. Most of the patients with prostatic hyperplasia or prostatic cancer had higher PSA concentrations than did subjects of ages less than 50 years or asymptomatic age-matched healthy subjects. Results compared favorably with those by an established technique relying on the use of radioactive label. Our method for measuring PSA in human serum is convenient, inexpensive, and well compatible with present clinical practice.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
F. T. Kreutz and M. R. Suresh
Novel bispecific immunoprobe for rapid and sensitive detection of prostate-specific antigen
Clin. Chem., April 1, 1997; 43(4): 649 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Herrala, R. Kurkela, K. Porvari, R. Isomaki, P. Henttu, and P. Vihko
Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein
Clin. Chem., February 1, 1997; 43(2): 279 - 284.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.